Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2012-03-16 Transaction in Own Shar…
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares 2012
Transaction in Own Shares Classification · 98% confidence The document is titled 'Aktietilbagekøbsprogram – meddelelse nr. 18' (Share Buyback Program - Announcement No. 18) and details the transactions made under an ongoing share buyback program ('Aktietilbagekøb i ALK'). It provides specific daily and accumulated data on the number of shares repurchased and the total amount spent in DKK. This directly relates to the company managing its own stock, which corresponds to the definition of 'Transaction in Own Shares' (POS). The document is a specific regulatory announcement detailing these transactions, not a general report or a mere announcement of a report's publication.
2012-03-16 English
Transaction in Own Shares 2012
Transaction in Own Shares Classification · 100% confidence The document text explicitly discusses an ongoing 'aktietilbagekøbsprogram' (share buyback program) initiated on November 15, 2011. It details the maximum amount, the period, and provides a weekly accumulation table showing the number of shares repurchased ('Tilbagekøbte aktier, stk.') and the total amount spent in DKK for specific trading days. This content directly relates to the company purchasing its own shares, which corresponds to the definition of 'Transaction in Own Shares'. The code for this is POS.
2012-03-09 Danish
Transaction in Own Shares 2012
Transaction in Own Shares Classification · 100% confidence The document explicitly details the weekly progress of a share buy-back programme initiated by ALK-Abelló A/S. It provides transaction details (number of shares bought back, average price, amount) for specific trading days and reports the accumulated total shares bought back and the company's current holding of own shares. This content directly corresponds to the definition of a report concerning the company buying back or selling its own shares, which maps to the 'Transaction in Own Shares' category.
2012-03-09 English
Capital/Financing Update 2012
Capital/Financing Update Classification · 95% confidence The document is a press release dated March 8, 2012, announcing a specific corporate action: an investment of 18 million EUR to expand production facilities in France to support existing products and introduce a new product (SLIToneULTRA®). It discusses capital expenditure expectations for 2012 but does not contain full financial statements or detailed quarterly/annual results. This type of announcement, focusing on a specific financing/investment decision related to capital structure or fundraising for expansion, aligns best with the 'Capital/Financing Update' category.
2012-03-08 English
Regulatory Filings 2012
Regulatory Filings Classification · 100% confidence The document is a press release dated March 8, 2012, announcing a specific corporate action: an investment of 18 million EUR to expand production facilities in France to meet demand and prepare for a new product launch (SLIToneULTRA®). It discusses capital expenditure (CAPEX) related to facilities and confirms that this decision does not change the existing financial outlook for 2012. This content directly relates to financing activities, capital structure changes, or significant investment decisions that are not standard periodic financial reporting (like 10-K or IR). It fits best under 'Capital/Financing Update' (CAP) as it details a major investment decision impacting future capital deployment, or potentially 'Regulatory Filings' (RNS) if it were a general announcement. Given the specific nature of announcing a significant capital investment plan, CAP is the most precise fit over the general RNS fallback. The document length (2711 chars) suggests it is an announcement, not a full report.
2012-03-08 Danish
Regulatory Filings 2012
Regulatory Filings
2012-03-05 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.